Progressive cardiac dysfunction in adriamycin-induced cardiomyopathy rats

被引:59
作者
Teraoka, K [1 ]
Hirano, M [1 ]
Yamaguchi, K [1 ]
Yamashina, A [1 ]
机构
[1] Tokyo Med Coll, Dept Internal Med 2, Shinjuku Ku, Tokyo 1600023, Japan
关键词
heart failure; animal studies;
D O I
10.1016/S1388-9842(00)00111-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiotoxicity is a limiting factor in the treatment of cancer with adriamycin. We administered adriamycin by a method which minimizes the risk of peritonitis in an adriamycin-induced cardiomyopathy rat model. Sixty male Wistar rats were given 1 mg/kg of adriamycin intraperitoneally 1.5 times over a 3-week period (total dose, 15 mg/kg) to induce the cardiomyopathy model. Fifteen control rats received 10 ml/kg body wt. saline 15 times over 3 weeks. The animals were observed for 12 weeks and assessed for mortality, and cardiac volume and function was analyzed by echocardiography at 4, 8, and 12 weeks. In rats treated with adriamycin, the cumulative :mortality was 35.8% while in the controls, none of the rats died. Left ventricular diameter of the systole (LVDs) was significantly increased at 4 weeks (4.5 vs. 3.3 mm; P < 0.001). Left ventricular diameter of the diastole (LVDd) was significantly increased at 12 weeks (7.9 vs. 7.0 mm; P < 0.01) and the % fractional shortening (FS) was significantly decreased at 8 weeks (33.4% vs. 50.0%; P < 0.01) in the adriamycin-treated rats. This administration method appears to be useful for investigating the cardiac effect of adriamycin while avoiding the influence of peritonitis typically caused by an intraperitoneal injection of higher single doses of adriamycin. (C) 2000 European Society of Cardiology. All rights reserved.
引用
收藏
页码:373 / 378
页数:6
相关论文
共 21 条
[1]   LOWER INCIDENCE OF DOXORUBICIN-INDUCED CARDIOMYOPATHY BY ONCE-A-WEEK LOW-DOSE ADMINISTRATION [J].
ANDERS, RJ ;
SHANES, JG ;
ZELLER, FP .
AMERICAN HEART JOURNAL, 1986, 111 (04) :755-759
[2]   OXIDATIVE STRESS IN MOUSE HEART BY ANTITUMORAL DRUGS - A COMPARATIVE-STUDY OF DOXORUBICIN AND MITOXANTRONE [J].
ARNAIZ, SL ;
LLESUY, S .
TOXICOLOGY, 1993, 77 (1-2) :31-38
[3]  
BILLINGHAM ME, 1979, HUM PATHOL, V10, P376
[4]   Propolis protects against doxorubicin-induced myocardiopathy in rats [J].
Chopra, S ;
Pillai, KK ;
Husain, SZ ;
Giri, DK .
EXPERIMENTAL AND MOLECULAR PATHOLOGY, 1995, 62 (03) :190-198
[5]   MODULATION OF GLUTATHIONE AND GLUTATHIONE-DEPENDENT ANTIOXIDANT ENZYMES IN MOUSE HEART FOLLOWING DOXORUBICIN THERAPY [J].
GUSTAFSON, DL ;
SWANSON, JD ;
PRITSOS, CA .
FREE RADICAL RESEARCH COMMUNICATIONS, 1993, 19 (02) :111-120
[6]   ADRIAMYCIN-INDUCED MYOCARDIAL LESIONS - REPORT OF A WORKSHOP [J].
JAENKE, RS ;
FAJARDO, LF .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1977, 1 (01) :55-60
[7]  
JENSEN RA, 1984, J CARDIOVASC PHARM, V6, P186
[8]   Suppression of cardiotoxicity by overexpression of catalase in the heart of transgenic mice [J].
Kang, YJ ;
Chen, Y ;
Epstein, PN .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (21) :12610-12616
[9]  
Kawasaki N, 1996, J Card Fail, V2, P293, DOI 10.1016/S1071-9164(96)80016-9
[10]  
Kim Chin, 1997, Life Sciences, V60, P75